doravirine + emtricitabine + tenofovir disoproxil fumarate

Doravirine + emtricitabine + tenofovir disoproxil fumarate is an oral fixed-dose combination antiretroviral medication used as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. The combination acts by lowering the levels of HIV in the blood and boosting immune function, but does not cure or prevent HIV or AIDS. - Doravirine is a **non-nucleoside reverse transcriptase inhibitor (NNRTI)**, blocking HIV reverse transcriptase by binding non-competitively, thereby preventing viral replication. - Emtricitabine and tenofovir disoproxil fumarate are **nucleoside analogue reverse transcriptase inhibitors (NRTI)**; they are incorporated into viral DNA by reverse transcriptase and act as chain terminators, blocking viral DNA synthesis. This regimen is approved for treatment-naive patients or as a switch for virologically suppressed patients meeting clinical criteria. The principal developer and manufacturer is Merck Sharp & Dohme. Adverse effects may include renal toxicity and exacerbation of hepatitis B if discontinued in co-infected patients[2][3][4][5][6].

Other names

doravirine + emtricitabine + tenofovir disoproxil fumarate